复宏汉霖：HLX17完成首例患者给药

Core Viewpoint - The company has completed the first patient dosing in an international multicenter Phase 1 clinical study of its self-developed biosimilar HLX17, aimed at evaluating its pharmacokinetics, efficacy, safety, and immunogenicity compared to KEYTRUDA in patients with various resected solid tumors [2] Group 1 - The clinical study is a multicenter, randomized, double-blind, parallel-controlled Phase 1 trial [2] - The study focuses on patients with multiple resected solid tumors [2] - HLX17 is a recombinant humanized monoclonal antibody targeting PD-1 [2]